Au-24 as a potential thioredoxin reductase inhibitor in hepatocellular carcinoma cells. (March 2022)

• Record Type: Journal Article
• Authors: Dong, Gaopan; Ye, Xiaohan; Wang, Shumei; Li, Wenhua; Cai, Rong; Du, Lupei; Shi, Xiaodong; Li, Minyong
• Is Part Of: Pharmacological research. Volume 177(2022)
• Publication Date: 2022-03
• Subjects: Thioredoxin reductase (TrxR) inhibitor -- Signaling pathways -- Apoptosis -- Hepatocellular carcinoma (HCC); Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106113
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: A novel TrxR inhibitor Au-24 and its inhibitory ability to hepatocellular carcinoma in vitro and in vivo is reported herein. Au-24 can suppress HepG2 cells from proliferating by lowering mitochondrial membrane potential (MMP) and increasing reactive oxygen species (ROS) levels, resulting in oxidative stress, which causes DNA damage, autophagy, cell cycle arrest, and apoptosis. This compound can also affect the normal function of apoptosis, MAPK, PI3K/AKT/mTOR, NF-κB, STAT3 signaling pathways. In vivo experiments revealed that Au-24 inhibited HepG2 tumor growth more effectively than AA1 (chloro(triethylphosphine)gold(I)) by decreasing Ki67 and CD31 protein expression and promoting tumor cell apoptosis and necrosis lesions. As a result, Au-24 was found to be a promising candidate as a TrxR inhibitor for the treatment of hepatocellular carcinoma (HCC) in both in vivo and in vitro experiments. Graphical Abstract: ga1